Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel as primary treatment for acromegaly with pituitary macroadenoma
NL-OMON35454Phase 3Active, not recruiting
- Sponsor
- Ipsen
- Start
- Jun 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in acromegaly and gigantism, sponsored by Ipsen. Primary endpoint: Change in pituitary tumor volume at Week 48. Started Jun 2008; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
acromegalygigantism
Beyond the preview
Go deeper on NL-OMON35454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35454.